Merck Maintains Growth Trajectory For Vytorin, Zetia – For Now
This article was originally published in The Pink Sheet Daily
Executive Summary
Company gets subpoenas from New York State Attorney General, acknowledges as many as 50 civil class action suits over ENHANCE trial.
You may also be interested in...
Merck Gets Janumet Label Extended
Combo drug’s new indications follow similar extensions last year for the pair when taken in tandem.
Merck Gets Janumet Label Extended
Combo drug’s new indications follow similar extensions last year for the pair when taken in tandem.
Schering-Plough Hopes To Enhance Confidence In Vytorin/Zetia With Monthly Rx Data
Firm feeling impact on sales from Vytorin study results.